Wockhardt (NSE:WOCKPHARMA) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WOCKPHARMA Wockhardt Ltd NSE:WOCKPHARMA
61 GF Score
Price ₹1,865.20
GF Value ₹1,246.45
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Wockhardt Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

NSE:WOCKPHARMA
61GF Score
Wockhardt Ltd NSE:WOCKPHARMA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued. The current stock price of ₹1,865.20 is trading 49.6% above its estimated GF Value™ of ₹1,246.45. GuruFocus considers Wockhardt to be Significantly Overvalued.

Key valuation signals for NSE:WOCKPHARMA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: ₹1,246.45 vs. price of ₹1,865.20 (49.6% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wockhardt Business Description

Other Exchanges 532300:India
Address Bandra-Kurla Complex, Wockhardt Towers, Bandra East, Mumbai, MH, IND, 400051
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
61GF Score

Get the complete analysis for NSE:WOCKPHARMA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,865.20
Price
₹1,246.45
GF Value